By using the Cambridge Cognition website, without changing your settings, you agree to our use of cookies to enhance your browsing experience.x MENU CMS Entry id: 2710 | Channel: News landing page | Template: news/index Search Login Company News News 26 October 2021 Cambridge Cognition wins contract for a pivotal schizophrenia trial Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer. Read on 6 August 2021 Cambridge Cognition: COVID-19 Update We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally. Read on 1 July 2021 Spin-out of Monument Therapeutics Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system ("CNS") disorders. Read on 28 June 2021 New £2.2 million contract for at-home cognitive testing in a virtual clinical trial Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021. Read on 11 June 2021 Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner Cambridge Cognition Holdings is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders. Read on 26 April 2021 Cognition and COVID-19: CANTAB Research Grant - Results The results of the 2021 CANTAB Research Grant are in! This year's award was focussed on the connection between cognition and COVID-19. Read on 8 April 2021 Cambridge Cognition provides cognitive assessments in an at-home clinical trial Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial. The contract is worth approximately £0.5 million. Read on 1 2 3 > Last › Press Enquiries If you have a press enquiry, please get in touch. Contact us Research products Conduct high impact research with gold standard cognitive assessments View our products Tel: +44 (0)1223 810 700 Email: info@camcog.com Home What we do Services Products Technology Resources About Contact Careers Privacy Terms of use Investors Copyright © 2021 Cambridge Cognition Ltd All rights reserved Registered in England and Wales Company no. 4338746